A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Clinical trial NCT06637423 · RECRUITING

Trial details

NCT number: NCT06637423
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Muscle Invasive Bladder Cancer

Start date: 2024-12-20
Primary completion: 2029-03-14
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.